But it provides almost no protein
What ultimately may hold more promise for less well-resourced patients in either Medicaid or the program for the elderly and certain disabled groups, Medicare, are the agreements Novo Nordisk and Eli Lilly reached with the Trump administration on selling GLP-1 treatments for $245 a month to the public insurers
Nygrd O, Refsum H, Ueland PM, Stensvold I, Nordrehaug JE, Kvle G, and Vollset SE (1997b)
What Are the Cardiovascular Outcomes of Semaglutide in Patients With Type 2 Diabetes and Cardiovascular Disease
Some patients using compounded versions have experienced: Unexpected gastrointestinal distress Severe nausea and vomiting Signs of allergic reactions or infections Compounded medications lack FDA review , risking their safety, efficacy, and sterility
Switching Compounds vs